Sanofi and Regeneron announced that the first patient outside of the U.S. has been treated as part of its global clinical evaluation of Kervaza (sarilumab) in patients with severe COVID-19.

The multi-center phase 2/3 trial will assess the safety and efficacy of a single intravenous dose of Kevzara along with supportive care, compared to supportive care plus placebo.

The drugmakers said the trial will recruit approximately 300 hospitalized patients who are severely or critically ill with COVID-19.